Related Experiment Video

Updated: May 10, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

AKT1 inhibitory DNAzymes inhibit cell proliferation and migration of thyroid cancer cells

Le Yang1, Jin-Ting He, Hong Guan

  • 1Department of Endocrinology, The People's Hospital of Jilin Province, Changchun, China.

Asian Pacific Journal of Cancer Prevention : APJCP
|June 4, 2013
PubMed

Insights

This study developed AKT1-targeting DNAzymes for thyroid cancer. AKT1-DRz1 effectively reduced AKT1 expression, inhibiting cancer cell proliferation and invasion.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • AKT1, a serine/threonine kinase, is implicated in thyroid cancer progression.
  • Overexpression of AKT1 is observed in thyroid tumors, driving cancer metabolism, growth, and survival.

Purpose of the Study:

  • To design and evaluate AKT1-specific DNAzymes for targeting AKT1 mRNA in thyroid cancer.
  • To assess the anti-tumorigenic effects of these DNAzymes in vitro.

Main Methods:

  • Design of two AKT1-specific DNAzymes (DRz1 and DRz2) targeting AKT1 mRNA.
  • Evaluation of DNAzyme efficacy in reducing AKT1 expression and its impact on SW597 thyroid cancer cells.

Main Results:

  • DRz1 demonstrated a 58% decrease in AKT1 expression.
  • DRz1 significantly inhibited cell proliferation, induced apoptosis, and reduced invasion in SW597 cells.
  • Down-regulation of survivin, caspase-3, VEGF, and MMP2 was observed following DRz1 treatment.

Conclusions:

  • AKT1-DRz1 exhibits significant anti-tumorigenic activity in thyroid cancer cells.
  • AKT1-DRz1 shows potential as a novel therapeutic strategy for thyroid cancer treatment.

More Related Videos

Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...